AIF APAC Holds 5th Annual Investors’ Meeting with Events in Seoul and Tokyo
The day in focus. Delivered to your inbox.
A concise daily briefing of key stories, insights and developments, selected by our editorial team.
By subscribing, you agree to our Privacy Policy. Unsubscribe at any time.More to Read
Dimensional Fund Advisors Ltd. : Form 8.3 - SPIRE HEALTHCARE GROUP PLC - Ordinary Shares
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Dimensional Fund Advisors Ltd. whose parent is Dimensional Fund Advisors LP, and also on behalf their investment advisory affiliates (“Dimensional”). The Dimensional entities are investment advisors and Dimensional expressly disclaims beneficial ownership of the shares des
Dimensional Fund Advisors Ltd. : Form 8.3 - DCC Energy PLC - Ordinary Shares
FORM 8.3 IRISH TAKEOVER PANEL OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE 1. KEY INFORMATION (a) Full name of discloser Dimensional Fund Advisors Ltd. in its capacity as investment advisor and on behalf its affiliates who are also investment advisors (”Dimensional”). Dimensional expressly disclaims beneficial ownership of the shares described in t
Form-8.3 ADVANCED MEDICAL SOLUTIONS GROUP PLC - 09 11 2026 - (CGWL)
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients) (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must
Form 8.5 (EPT/RI)-Advanced Medical Solutions Group Plc
FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Name of exempt principal trader: Investec Bank Plc (b) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree Advanced Medical Solutions Group Plc (c) Name of the party to the offer with which exempt principal tra
Form 8.5 (EPT/RI)-Gamma Communications Plc
FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Name of exempt principal trader: Investec Bank plc (b) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree Gamma Communications Plc (c) Name of the party to the offer with which exempt principal trader is conne
CREDIT AGRICOLE S.A. ANNOUNCES REDEMPTION OF GBP 500,000,000 Subordinated Fixed Rate Resettable Notes issued on 9 June 2021 (ISIN: FR0014003W84)*
Montrouge, November 10, 2026 CREDIT AGRICOLE S.A. ANNOUNCES REDEMPTION OF GBP 500,000,000 Subordinated Fixed Rate Resettable Notes issued on 9 June 2021 (ISIN: FR0014003W84)* Crédit Agricole S.A. (the “ Issuer” ) announces today the redemption (the “ Redemption” ) with effect on 9 December 2026 (the “ Redemption Date” ) of all of its outstanding GBP 500,000,000 Subordinated Fixed Rate Resettable Notes issued on June 9, 2021 (ISIN: FR0014003W84) (the “ Notes” ) pursuant to Condition 6(e) ( Redemp
4BIO Capital leads $60M Series A financing of Oyster Therapeutics (formerly Kesmalea Therapeutics) to advance next-generation targeted protein degraders for Alzheimer’s and other neurodegenerative diseases
Proceeds to advance oral, brain-penetrant tau degrader into clinical development as a novel treatment for tau-driven diseases like Alzheimer’s Series A led by 4BIO Capital with participation from new investors, including Eli Lilly and Company, alongside existing investors Financing supports continued development of proprietary SELFTAC ® platform for generating small bifunctional targeted protein degraders with enhanced drug-like properties Establishes collaboration with leading tau researcher Dr
NBPE Announces Transaction in Own Shares
THE INFORMATION CONTAINED HEREIN IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO AUSTRALIA, CANADA, ITALY, DENMARK, JAPAN, THE UNITED STATES, OR TO ANY NATIONAL OF SUCH JURISDICTIONS Neuberger Private Equity Partners Announces Transaction in Own Shares St Peter Port, Guernsey 10 November 2026 Neuberger Private Equity Partners Limited (“NBPE” or the “Company”) today announces details of Class A Shares bought back pursuant to general authority granted by shareholders of the Company on 1
Comments (0)
Login to join the conversation
Login / RegisterNo comments yet. Be the first to comment!